NO20080951L - Farmasoytisk blanding for behandling av kardiovaskulaere lidelser - Google Patents

Farmasoytisk blanding for behandling av kardiovaskulaere lidelser

Info

Publication number
NO20080951L
NO20080951L NO20080951A NO20080951A NO20080951L NO 20080951 L NO20080951 L NO 20080951L NO 20080951 A NO20080951 A NO 20080951A NO 20080951 A NO20080951 A NO 20080951A NO 20080951 L NO20080951 L NO 20080951L
Authority
NO
Norway
Prior art keywords
immunotherapy
treatment
pharmaceutical composition
cardiovascular disorders
oxidized ldl
Prior art date
Application number
NO20080951A
Other languages
English (en)
Inventor
Roland Carlsson
Jan Nilsson
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of NO20080951L publication Critical patent/NO20080951L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Anvendelse av immunterapi mot oksidert LDL for å indusere regresjon av allerede eksisterende ateroskleroselesjoner i et individ. Immunterapien kan være passiv immunterapi ved bruk av antistoffer som bindes til epitoper til stede på oksidert LDL, eller aktiv immunterapi ved bruk av en vaksineblanding for induksjon av en immunrespons mot epitoper til stede på oksidert LDL.
NO20080951A 2005-09-02 2008-02-25 Farmasoytisk blanding for behandling av kardiovaskulaere lidelser NO20080951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517878.5A GB0517878D0 (en) 2005-09-02 2005-09-02 Immunotherapeutic treatment
PCT/EP2006/008594 WO2007025781A2 (en) 2005-09-02 2006-09-04 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques

Publications (1)

Publication Number Publication Date
NO20080951L true NO20080951L (no) 2008-06-02

Family

ID=35220745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080951A NO20080951L (no) 2005-09-02 2008-02-25 Farmasoytisk blanding for behandling av kardiovaskulaere lidelser

Country Status (16)

Country Link
US (1) US20090208503A1 (no)
EP (2) EP1928913B1 (no)
JP (1) JP2009506995A (no)
KR (2) KR20120101074A (no)
CN (1) CN101316863A (no)
AU (1) AU2006286729A1 (no)
BR (1) BRPI0615313A2 (no)
CA (1) CA2621017A1 (no)
GB (1) GB0517878D0 (no)
IL (1) IL189847A (no)
NO (1) NO20080951L (no)
NZ (1) NZ566237A (no)
RU (1) RU2454428C2 (no)
UA (1) UA96275C2 (no)
WO (1) WO2007025781A2 (no)
ZA (1) ZA200801959B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
EP2240156A2 (en) * 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2012074725A2 (en) * 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2592423A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2019210207A2 (en) * 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2019215300A1 (en) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Antibodies for use in combination therapy
WO2019232081A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
JP7722989B2 (ja) 2019-11-12 2025-08-13 アブセントラ，エルエルシー がんを治療するための方法及び組成物
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2025151504A1 (en) * 2024-01-08 2025-07-17 Abcentra, Llc Compositions and methods for reducing risk of major adverse cardiovascular event
WO2026165210A1 (en) * 2025-01-30 2026-08-06 Abcentra, Llc Treatment regimens for reducing risk of major adverse cardiovascular event

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20030157567A1 (en) * 1999-09-20 2003-08-21 Joe Lunec Oxidised fragments of apolipoprotein B and their use
US6716410B1 (en) * 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
AU2001233277B2 (en) * 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
DE10059930A1 (de) * 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE10123074A1 (de) 2001-05-10 2002-11-14 Monforts Textilmaschinen Gmbh Vorrichtung zur Wärmebehandlung einer Warenbahn
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
CA2500895A1 (en) 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis

Also Published As

Publication number Publication date
BRPI0615313A2 (pt) 2012-12-04
WO2007025781A3 (en) 2007-05-03
EP1928913A2 (en) 2008-06-11
CN101316863A (zh) 2008-12-03
KR20080053483A (ko) 2008-06-13
IL189847A (en) 2012-02-29
RU2008112664A (ru) 2009-10-10
GB0517878D0 (en) 2005-10-12
EP2319868A1 (en) 2011-05-11
US20090208503A1 (en) 2009-08-20
JP2009506995A (ja) 2009-02-19
IL189847A0 (en) 2008-11-03
KR20120101074A (ko) 2012-09-12
UA96275C2 (ru) 2011-10-25
WO2007025781A2 (en) 2007-03-08
RU2454428C2 (ru) 2012-06-27
NZ566237A (en) 2011-07-29
AU2006286729A1 (en) 2007-03-08
CA2621017A1 (en) 2007-03-08
ZA200801959B (en) 2009-08-26
EP1928913B1 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
CL2016001254A1 (es) Mólecula unión cd3 capaz de unirse a cd3 humanos y no humanos (divisional de sol. 3329-13).
NO20074637L (no) Ressursautorisering omfattende ontologi
EA201170381A1 (ru) Получение сквалена из гиперпродуцирующих дрожжей
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
WO2007011941A3 (en) Human anti-b7rp1 neutralizing antibodies
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
PE20140825A1 (es) Anticuerpos contra il-6 y sus usos
NO20071090L (no) Behandling av pulmonal hypertensjon ved inhalert iloprost med en mikropartikkelformulering.
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
AR083747A1 (es) Anticuerpos anti-il-23
AU2010217100A8 (en) Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
HK1250737A1 (zh) 结合cd79的抗体分子
ECSP10010295A (es) Formulacion de anticuerpo
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
JP2007520566A5 (no)
NO20065252L (no) Behandling av forstyrrelser
AR065312A1 (es) Nuevos anticuerpos
EA201270124A1 (ru) Новые терапевтические и диагностические средства
EP4678660A3 (en) Antibody against activin receptor type ii receptor for use in treating heart failure
NO20072290L (no) Organiske forbindelser.
NO20061412L (no) Terapi av okulaere foretyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application